FDA Drug Recalls

Recalls / Class III

Class IIID-0349-2019

Product

Aprepitant Capsules, USP 40 mg, 1 capsule Unit Blister Pack, Rx Only, Manufactured in India for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430. UPC 368462583401. NDC 68462-583-40

Brand name
Aprepitant
Generic name
Aprepitant
NDCs
68462-112, 68462-583, 68462-584, 68462-585
FDA application
ANDA207777
Affected lot / code info
Lot: 17180918, EXP June 2020

Why it was recalled

Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.

Recalling firm

Firm
Glenmark Pharmaceuticals Inc., USA
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
750 Corporate Dr, Mahwah, New Jersey 07430-2009

Distribution

Quantity
5,016 blister packs
Distribution pattern
Nationwide

Timeline

Recall initiated
2018-11-27
FDA classified
2019-01-07
Posted by FDA
2018-12-26
Terminated
2019-09-12
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0349-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.